Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company was founded in 1969 and is based in Washington, the District of Columbia.
DHR Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Danaher Corp. To summarize, we found that Danaher Corp ranked in the 23th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for DHR, they are:
The company's debt burden, as measured by earnings divided by interest payments, is 19.17 -- which is good for besting 81.02% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
DHR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 31.16% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
WAT, CDNA, CNC, IDXX, and ILMN can be thought of as valuation peers to DHR, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Centrifuges help in the separation of two different substances, which have a difference in their densities. They can also be essentially used to separate densities with almost indistinguishable densities. Additionally, they can be used to separate insoluble particulates in a
ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Blood Management Devices Key Trends and Opportunities to 2026”. The Global Blood Management Devices Market Report is a professional and in-depth study on the current state of
According to the new market research report "Clinical Microbiology Market by Application (Food, Pharma, Manufacturing, Chemical, Environment), Disease (Respiratory, Std, Uti), Product (Instrument, Analyzer, Reagent), End User (Hospital, Diagnostic Lab, Academia) - Global Forecast to 2025", published by MarketsandMarkets™, the